Shanghai Denovo officially launches Phase I clinical study of a new TLR8 agonist DN1508052-01
2020-09-17
On September 10, Shanghai Denovo PharmaceuticalTechnology Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, held aTLR8 agonist DN1508052-01 Phase I clinical trial kick-off meeting at ShanghaiDongfang Hospital, officially launching the project's Phase I clinical study.
Next：This is the last one
Prev：This is the first article